Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.50 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.50 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL9685458 | 0.92 | SLC18A3 (0.53) | SMN1; SMN2TP53ALDH1A1LMNAMAPT | |
| SCHEMBL8025878 | 0.88 | LMNA (0.59) | SMN1; SMN2TP53ALDH1A1LMNAMAPT | |
| SCHEMBL346325 | 0.88 | LMNA (0.59) | SMN1; SMN2TP53ALDH1A1LMNAMAPT | |
| SCHEMBL28722738 | 0.88 | LMNA (0.59) | SMN1; SMN2TP53ALDH1A1LMNAMAPT | |
| Glycolic Acid SCHEMBL2763521 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2TP53ALDH1A1LMNAMAPT | |
| SCHEMBL11282272 | 0.86 | SLC18A3 (0.51) | SMN1; SMN2TP53ALDH1A1LMNAMAPT | |
| SCHEMBL43080 | 0.85 | SLC18A3 (0.56) | SMN1; SMN2TP53ALDH1A1LMNAMAPT | |
| Bicarbonate SCHEMBL1720129 | 0.84 | NPC1 (0.48) | SMN1; SMN2TP53ALDH1A1LMNAMAPT | |
| Acetic Acid SCHEMBL7274837 | 0.82 | KMO (0.55) | SMN1; SMN2ALDH1A1SLC18A3HDAC8HDAC6 | |
| SCHEMBL18117721 | 0.82 | MAPT (0.54) | SMN1; SMN2TP53ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-6221367-B1 | EXPOSING A BIOLOGICALLY ACTIVE AGENT TO A COMPLEXING PERTURBANT TO REVERSIBLY TRANSFORM THE BIOLOGICALLY ACTIVE AGENT TO THE INTERMEDIATE STATE AND TO FORM A TRANSPORTABLE SUPRAMOLECULAR COMPLEX | EMISPHERE TECHNOLOGIES, INC. | 2001-04-24 | — | — | US | claimed |
| US-6071538-A | TRANSPORTATION ACROSS CELL MEMBRANE OR LIPID BILAYER | EMISPHERE TECHNOLOGIES, INC. (US) | 2000-06-06 | — | — | US | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | disclosed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| US-20050255138-A1 | Active agent transport systems | MHR INSTITUTIONAL PARTNERS IIA LP | 2005-11-17 | — | — | US | disclosed |
| US-6916489-B2 | Active agent transport systems | EMISPHERE TECHNOLOGIES, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1021169-A4 | ACTIVE AGENT TRANSPORT SYSTEMS | EMISPHERE TECH INC (US) | 2004-07-07 | — | — | EP | disclosed |
| US-6099856-A | INCREASED BIOAVAILABLE | EMISPHERE TECHNOLOGIES, INC. (US) | 2000-08-08 | — | — | US | disclosed |
| EP-1021169-A1 | ACTIVE AGENT TRANSPORT SYSTEMS | Emisphere Technologies, Inc. (US) | 2000-07-26 | — | — | EP | disclosed |
| US-6071538-A | TRANSPORTATION ACROSS CELL MEMBRANE OR LIPID BILAYER | EMISPHERE TECHNOLOGIES, INC. (US) | 2000-06-06 | — | — | US | disclosed |
| WO-1999016427-A1 | ACTIVE AGENT TRANSPORT SYSTEMS | EMISPHERE TECHNOLOGIES, INC. (US) | 1999-04-08 | — | — | WO | disclosed |
| WO-1998025589-A1 | ACTIVE AGENT TRANSPORT SYSTEMS | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-06-18 | — | — | WO | disclosed |
| US-5714167-A | REVERSIBLY FORMING SUPRAMOLECULAR COMPLEX OF ACTIVE AGENT WITH PERTURBANT; DRUG DELIVERY | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| US-5541155-A | MIXTURES WITH PEPTIDES, MUCOPOLYSACCHARIDES, CARBOHYDRATES, LIPIDS, PESTICIDES, CROMOLYN SODIUM AND DESFERRIOXAMINE | EMISPHERE TECHNOLOGIES, INC. (US) | 1996-07-30 | — | — | US | disclosed |
| WO-1995028920-A1 | ACIDS AND ACID SALTS AND THEIR USE IN DELIVERY SYSTEMS | EMISPHERE TECHNOLOGIES, INC. (US) | 1995-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050255138-A1 | Active agent transport systems | ABCB11, SLC47A1, ABCB4 | SMN1; SMN2 3349/4885TP53 1094/4885ALDH1A1 2173/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | SMN1; SMN2 366/4885TP53 3214/4885ALDH1A1 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.